Swedish Orphan Biovitrum AB: Sobi and Selecta Biosciences announce completion of enrolment in DISSOLVE Phase 3 study evaluating SEL-212 for chronic refractory gout
STOCKHOLM, Dec. 1, 2021 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi) (STO: SOBI) and Selecta Biosciences, Inc. (NASDAQ: SELB), today announced the completion of enrolment for DISSOLVE